Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AC201 is a topical live biotherapeutic product (LBP) developed by Shenzhen 01 Life Technology (01Life) for the treatment of acne. As a microbiome-based therapy, it utilizes live microorganisms to modulate the skin's microbial ecosystem, aiming to restore balance and address the underlying causes of acne vulgaris. AC201 has successfully completed Phase 1 clinical trials and is currently positioned for licensing-out opportunities.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AC201.